Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342975 · ClinicalTrials.gov registry record · Phase 2
Protection From Acute Kidney Injury (AKI) With Basis™ Treatment
A Phase 2 study of AKI, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT04342975 is a Phase 2 study of AKI that has completed, run by Mayo Clinic. The registered enrollment target is 54 participants, below the 78-participant average among 4 other AKI trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04342975, a Phase 2 study of AKI, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic aneurysm repair and open aortic arch reconstruction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nicotinamide Riboside + Pterostilbene
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2024-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04342975
The ClinicalTrials.gov registry entry for NCT04342975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 4 other AKI trials with a reported enrollment target (31% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AKI appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04342975 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04342975 about?
NCT04342975 is a clinical study titled "Protection From Acute Kidney Injury (AKI) With Basis™ Treatment". This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic an...
What is the current status of trial NCT04342975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-12-01. Estimated completion is 2024-03-14.
What conditions does trial NCT04342975 study?
This clinical trial studies the following conditions: AKI.
What interventions are being tested in trial NCT04342975?
The interventions under investigation include: Placebo (DRUG), Nicotinamide Riboside + Pterostilbene (DRUG).
Who is sponsoring clinical trial NCT04342975?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04342975 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AKI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery
COMPLETED · Phase 2
-
NO During CPB in Neonates to Reduce Risk of AKI
RECRUITING · Phase 3
-
Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2
RECRUITING · NA
-
Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.